ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025.
Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...
Revenue by product segment and geography Revenue grew from DKK 115.6 million to DKK 124.6 million in Q1 2025/26, a year-on-year increase of 8% that was driven by higher sales of instruments, ...
EssilorLuxottica étend sa plateforme de solutions de gestion de la myopie avec les verres Essilor Stellest 2.0, des lunettes connectées et une solution innovante pour adresser la pré-myopie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback